HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

HER2+ mBC: Safety and Tolerability in HER2CLIMB

May 18th 2020

HER2CLIMB: Implications for Brain Metastases in HER2+ mBC

May 18th 2020

Exciting Results From HER2CLIMB in HER2+ mBC

May 18th 2020

Relapsed/Refractory HER2+ mBC: Evolving Treatment Landscape

May 18th 2020

Tucatinib Approval Adds Impact to HER2+ Breast Cancer Paradigm

May 15th 2020

Therapeutic options for pretreated HER2-positive breast cancer now include tucatinib (Tukysa) as part of a triplet regimen with a tolerable safety profile that promises improved quality of life.

Looking Forward to a New Wave of Breast Cancer Therapies

May 14th 2020

The degree to which nature and nurture affect disease has long been debated in medicine, and it is an issue that esteemed breast cancer researcher and medical oncologist Joyce A. O’Shaughnessy, MD, has been working to unravel for her patients throughout a career that spans more than 30 years.

Tucatinib Approved in Switzerland for HER2-Positive Breast Cancer

May 12th 2020

Tucatinib has been approved in Switzerland for use in combination with trastuzumab and capecitabine for patients with previously treated metastatic HER2-positive breast cancer.

Optimizing Perioperative Treatment Strategies in TNBC

May 8th 2020

TNBC: Using Checkpoint Inhibitors Alone or With Chemotherapy

May 8th 2020

IMpassion130: Addressing Immune-Related AEs in TNBC Management

May 8th 2020

Analysis of IMpassion130: PD-L1 Testing in Advanced TNBC

May 8th 2020

TNBC: Updated Efficacy Results From IMpassion130

May 8th 2020

Adjuvant I/O in TNBC

May 8th 2020

ICI Combination Therapy Versus Monotherapy

May 8th 2020

PD-L1 Immune-Related Adverse Events

May 8th 2020

PD-L1 Assay PFS and OS Concordance

May 8th 2020

IMpassion130: Design and Preliminary Efficacy

May 8th 2020

Dr. Hamilton on the Evolution of Treatment in HER2+ Breast Cancer

May 8th 2020

Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Adjuvant Trastuzumab Emtansine Approved in UK for HER2+ Early Breast Cancer

May 7th 2020

Trastuzumab emtansine has been approved in the UK for the adjuvant treatment of patients with HER2-positive early breast cancer.

Dr. Crew on Recent Advances in HER2+ Breast Cancer

May 7th 2020

Katherine D. Crew, MD, MS, discusses recent advances made in HER2-positive breast cancer treatment.